000			03562nam a22004337a 4500
008			240723s20242024 xxu||||| |||| 00| 0 eng d
022			_a0160-564X
040			_aOvid MEDLINE(R)
099			_a38459758
245			_aMulticenter evaluation of left ventricular assist device implantation with or without ECMO bridge in cardiogenic shock.
251			_aArtificial Organs. 2024 Mar 08
252			_aArtif Organs. 2024 Mar 08
253			_aArtificial organs
260			_c2024
260			_p2024 Mar 08
265			_saheadofprint
265			_tPublisher
266			_d2024-07-23
520			_aBACKGROUND: The efficacy of extracorporeal membrane oxygenation (ECMO) as a bridge to left ventricular assist device (LVAD) remains unclear, and recipients of the more contemporary HeartMate 3 (HM3) LVAD are not well represented in previous studies. We therefore undertook a multicenter, retrospective study of this population.
520			_aCONCLUSIONS: Higher mortality was observed with ECMO as a bridge to LVAD, likely due to higher acuity illness, yet acceptable one-year survival was seen compared with historical rates. The receipt of the HM3 was associated with improved survival compared with older generation devices. Copyright © 2024 The Authors. Artificial Organs published by International Center for Artificial Organ and Transplantation (ICAOT) and Wiley Periodicals LLC.
520			_aMETHODS AND RESULTS: INTERMACS 1 LVAD recipients from five U.S. centers were included. In-hospital and one-year outcomes were recorded. The primary outcome was the overall mortality hazard comparing ECMO versus non-ECMO patients by propensity-weighted survival analysis. Secondary outcomes included survival by LVAD type, as well as postoperative and one-year outcomes. One hundred and twenty-seven patients were included; 24 received ECMO as a bridge to LVAD. Mortality was higher in patients bridged with ECMO in the primary analysis (HR 3.22 [95%CI 1.06-9.77], p = 0.039). Right ventricular assist device was more common in the ECMO group (ECMO: 54.2% vs non-ECMO: 11.7%, p < 0.001). Ischemic stroke was higher at one year in the ECMO group (ECMO: 25.0% vs non-ECMO: 4.9%, p = 0.006). Among the study cohort, one-year mortality was lower in HM3 than in HeartMate II (HMII) or HeartWare HVAD (10.5% vs 46.9% vs 31.6%, respectively; p < 0.001) recipients. Pump thrombosis at one year was lower in HM3 than in HMII or HVAD (1.8% vs 16.1% vs 16.2%, respectively; p = 0.026) recipients.
546			_aEnglish
650			_zAutomated
650			_aIN PROCESS -- NOT YET INDEXED
651			_aMedStar Washington Hospital Center
656			_aInternal Medicine Residency
656			_aMedStar Georgetown University Hospital/MedStar Washington Hospital Center
656			_aSurgery/Surgical Critical Care
657			_aJournal Article
700			_aBrahier, Mark _bMWHC
700			_aElliot, Tonya _bMWHC
700			_aMcGowan, Kevin _bMGUH _cInternal Medicine Residency _dMD
700			_aZaaqoq, Akram _bMWHC
790			_aSchurr JW, Ambrosi L, Fitzgerald J, Bermudez C, Genuardi MV, Brahier M, Elliot T, McGowan K, Zaaqoq A, Laskar S, Pope SM, Givertz MM, Mallidi H, Sylvester KW, Seifert FC, McLarty AJ
856			_uhttps://dx.doi.org/10.1111/aor.14740 _zhttps://dx.doi.org/10.1111/aor.14740
858			_yMcGowan, Kevin _uhttps://orcid.org/0000-0002-9542-3166 _zhttps://orcid.org/0000-0002-9542-3166
858			_yZaaqoq, Akram _uhttps://orcid.org/0000-0003-3147-5044 _zhttps://orcid.org/0000-0003-3147-5044
942			_cART _dArticle
999			_c14219 _d14219